Exploring best-practice manufacturing strategies for highly potent oral solid dosage forms
As the number of highly potent oral solid dose (HPOSD) drugs in development and on the market increases, so are regulator’s expectations regarding their safe manufacture. In this white paper Pfizer CentreOne examines what developers and their manufacturing partners need to know about its unique regulatory challenges and how to navigate HPOSD’s complex manufacturing environment successfully.
- Concepts and advice that improve HPOSD cGMP manufacturing compliance.
- Overview of regulatory models governing HPOSD manufacturing.
- Pfizer CentreOne’s integrated approach to HPOSD manufacturing safety.
You can download the full white paper by completing the form below.